Episode 16 - Neurofibromatosis Type 1-related Plexiform Neurofibromas: Key Advances from the 2025 Annual Oncology Conference (Chicago)

Practice Point® CME Podcasts: Expert Discussions in Rare Diseases™ di Practice Point Communications

Note sull'episodio

The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this podcast activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.

Launch Date: June 5, 2025

Release Date: June 5, 2025

Expiration Date: May 31, 2026

FACULTY

Amy Armstrong, MD

Assistant Professor of Pediatrics

Division of Hematology/Oncology

Neurofibromatosis (NF) Center

Washington University School of Medicine

St. Louis, Missouri

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditat ... 

 ...  Leggi dettagli